Androgen Receptor Pathway in Salivary Gland Cancer

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial. October 01, 2021 ARTICLE CITATION DOI: 10.1200/JCO.21.01983 Journal of Clinical Oncology - published online before print October 1, 2021 PMID: 34597118 Androgen Receptor Pathway in Salivary Gland Cancer Alan L. Ho , MD, PhD1,2xAlan L. HoSearch for articles by this author Show More 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY2Department of Medicine Weill Cornell Medical College, New York City, NY https://doi.org/10.1200/JCO.21.01983 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologySUPPORTA.L.H. is supported by the NIH/NCI Cancer Center Support Grant P30CA008748, NIH/NCI R01DE027738, and the Geoffrey Beene Cancer Research Center at Memorial Sloan Kettering Cancer Center.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTAndrogen Receptor Pathway in Salivary Gland CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Alan L. HoConsulting or Advisory Role: Bristol Myers Squibb, Eisai, Genzyme, Merck, Novartis, Sun Pharma, Regeneron, TRM Oncology, Ayala Pharmaceuticals, AstraZeneca, Sanofi, CureVac, Prelude Therapeutics, Kura Oncology, McGivney Global Advisors, Rgenta, AffyImmune Therapeutics, Exelixis, InxmedSpeakers' Bureau: Medscape, Omniprex America, NovartisResearch Funding: Lilly, Genentech/Roche, AstraZeneca, Bayer, Kura Oncology, Kolltan Pharmaceuticals, Eisai, AstraZeneca, Bristol Myers Squibb, Astellas Pharma, Novartis, Merck, Pfizer, Ayala Pharmaceuticals, Allos Therapeutics, Daiichi Sankyo, Elevar TherapeuticsTravel, Accommodations, Expenses: Janssen Oncology, Merck, Kura Oncology, Ignyta, Ayala Pharmaceuticals, Klus PharmaNo other potential conflicts of interest were reported. Companion Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial